Skip to main content

Table 3 Radiation equivalent doses in the tumour and normal organs for radioimmunoconjugates in NRG mice with s.c. HNSCC primary xenografts a

From: Dose predictions for [177Lu]Lu-DOTA-panitumumab F(ab′)2 in NRG mice with HNSCC patient-derived tumour xenografts based on [64Cu]Cu-DOTA-panitumumab F(ab′)2 – implications for a PET theranostic strategy

 

Radiation equivalent dose (Sv/MBq)

Organ

[64Cu]Cu-DOTA-panitumumab F(ab´)2 b

[177Lu]Lu-DOTA-panitumumab F(ab´)2 c

[177Lu]Lu-DOTA-panitumumab F(ab´)2 d

Comparison of doses for 177Lu calculated from 64Cu vs. 177Lu biodistribution (BOD)

(P-value)

Heart

0.03 ± 0.01

0.35 ± 0.06

0.32 ± 0.13

n.s.

Lungs

0.05 ± 0.01

0.51 ± 0.05

0.38 ± 0.04

n.s.

Liver

0.10 ± 0.02

1.22 ± 0.13

1.82 ± 0.14

0.03

Spleen

0.04 ± 0.01

0.71 ± 0.20

0.66 ± 0.18

n.s.

Pancreas

0.02 ± 0.01

0.26 ± 0.08

0.16 ± 0.04

n.s.

Stomach

0.03 ± 0.01

0.33 ± 0.03

0.27 ± 0.04

n.s.

Intestines

0.02 ± 0.00

0.31 ± 0.05

0.21 ± 0.05

n.s.

Kidneys

0.07 ± 0.01

0.63 ± 0.09

0.75 ± 0.08

n.s.

Tumour e

0.14 ± 0.03

2.00 ± 0.60

2.50 ± 0.80

n.s.

Whole Body

0.05 ± 0.00

0.26 ± 0.02

0.34 ± 0.02

0.05

  1. aEquivalent doses (D) were calculatd as D = Ãs × S × WR, where Ãs is the time-integrated activity in source organs obtained from BOD studies and S are the Snyder values for mice (Bitar et al., 2007; Xie and Zaidi, 2013) and WR is the radiation weighing factor
  2. bEquivalent doses for [64Cu]Cu-DOTA-panitumumab F(ab´)2
  3. cEquivalent doses for [177Lu]Lu-DOTA-panitumumab F(ab´)2 calculated based on the time-integrated activity for [64Cu]Cu-DOTA-panitumumab F(ab´)2 and using S-values for 177Lu
  4. dEquivalent doses for [177Lu]Lu-DOTA-panitumumab F(ab´)2 calculated based on the time-integrated activity for [177Lu]Lu-DOTA-panitumumab F(ab´)2 and using S-values for 177Lu
  5. eSelf-equivalent doses were estimated using the sphere model in OLINDA/EXM software based on the measured tumour volume for 64Cu or 177Lu